Consistent Outcomes across Dose Ranges with Titratable LixiLan, Insulin Glargine/Lixisenatide Fixed-Ratio Combination, in the LixiLan-O Trial

被引：0
|
作者：
Henry, Robert R.
Ahren, Bo
Davies, Melanie
Wu, Yujun
Handelsman, Yehuda
Souhami, Elisabeth
Niemoeller, Elisabeth
Rosenstock, Julio
机构：
来源：
DIABETES | 2016年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1017-P
引用
收藏
页码：A264 / A264
页数：1
相关论文
共 50 条
  • [1] Outcomes of LixiLan, a fixed-ratio combination of insulin glargine/lixisenatide, versus insulin glargine and lixisenatide by baseline characteristics: LixiLan-O trial
    Guerci, B.
    Davies, M.
    Leiter, L. A.
    Grunberger, G.
    Ampudia-Blasco, F.
    Yu, C.
    Stager, W.
    Niemoeller, E.
    Souhami, E.
    Rosenstock, J.
    [J]. DIABETOLOGIA, 2016, 59 : S384 - S384
  • [2] Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial
    Rosenstock, Julio
    Aronson, Ronnie
    Grunberger, George
    Hanefeld, Markolf
    Piatti, PierMarco
    Serusclat, Pierre
    Cheng, Xi
    Zhou, Tianyue
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Davies, Melanie
    [J]. DIABETES CARE, 2016, 39 (11) : 2026 - 2035
  • [3] Impact of Baseline HbA1c, BMI, and Diabetes Duration on the Efficacy and Safety of LixiLan (Insulin Glargine/Lixisenatide Titratable Fixed-Ratio Combination) vs. Insulin Glargine and Lixisenatide in the LixiLan-O Trial
    Davies, Melanie
    Leiter, Lawrence A.
    Grunberger, George
    Ampudia-Blasco, F. Javier
    Guerci, Bruno
    Yu, Christine
    Stager, William
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Rosenstock, Julio
    [J]. DIABETES, 2016, 65 : A268 - A268
  • [4] Clinical impact of LixiLan, a fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on oral agents: LixiLan-O trial
    Rosenstock, J.
    Aronson, R.
    Hanefeld, M.
    Piatti, P.
    Serusclat, P.
    Cheng, X.
    Zhou, T.
    Niemoeller, E.
    Souhami, E.
    Grunberger, G.
    Davies, M.
    [J]. DIABETOLOGIA, 2016, 59 : S384 - S385
  • [5] Postprandial glycaemic outcomes of a fixed-ratio combination of insulin glargine and lixisenatide in the LixiLan-L trial
    Vidal, J.
    Giorgino, F.
    Stager, W.
    Nikonova, E. V.
    Vlajnic, A.
    Perfetti, R.
    Meier, J.
    [J]. DIABETOLOGIA, 2016, 59 : S382 - S383
  • [6] Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents
    Davies, Melanie J.
    Leiter, Lawrence A.
    Guerci, Bruno
    Grunberger, George
    Javier Ampudia-Blasco, F.
    Yu, Christine
    Stager, William
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Rosenstock, Julio
    [J]. DIABETES OBESITY & METABOLISM, 2017, 19 (12): : 1798 - 1804
  • [7] Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial
    Rosenstock, Julio
    Diamant, Michaela
    Aroda, Vanita R.
    Silvestre, Louise
    Souhami, Elisabeth
    Zhou, Tianyue
    Perfetti, Riccardo
    Fonseca, Vivian
    [J]. DIABETES CARE, 2016, 39 (09) : 1579 - 1586
  • [8] Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials
    Davidson, J. A.
    Desouza, C.
    Fonseca, V.
    Frias, J. P.
    Van Gaal, L.
    Giorgino, F.
    Chao, J.
    Dex, T. A.
    Roberts, M.
    Saremi, A.
    Leiter, L. A.
    [J]. DIABETIC MEDICINE, 2020, 37 (02) : 256 - 266
  • [9] Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial
    Aroda, Vanita R.
    Rosenstock, Julio
    Wysham, Carol
    Unger, Jeffrey
    Bellido, Diego
    Gonzalez-Galvez, Guillermo
    Takami, Akane
    Guo, Hailing
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Bergenstal, Richard M.
    [J]. DIABETES CARE, 2016, 39 (11) : 1972 - 1980
  • [10] Efficacy and Safety across the Final Dose Ranges in Patients with T2DM Receiving Insulin Glargine/Lixisenatide Fixed-Ratio Combination in the LixiLan-L Trial
    Ritzel, Robert
    Vidal, Josep
    Aroda, Vanita R.
    Wu, Yujun
    Souhami, Elisabeth
    Niemoeller, Elisabeth
    Henry, Robert R.
    [J]. DIABETES, 2016, 65 : A266 - A267
12345